Dr Jim Withers and Dave Lettrich join Ethics talk to discuss how street outreach programs help mitigate harms of drug use among people experiencing homelessness.
Douglas E. Paull, MD, MS and Paul N. Uhlig, MD, MPA
Risk managers can help patient-subjects and clinician-researchers make informed novel device implantation decisions in the absence of preclinical trial data.
AMA J Ethics. 2020; 22(11):E911-918. doi:
10.1001/amajethics.2020.911.
The authors of a recent journal article believe that most doctors and clinical trial sponsors would not object to changes in regulations requiring doctors to disclose financial incentives to their patients.
Dr Oluwole Jegede joins Ethics Talk to discuss his article, coauthored with Drs Julio C. Nunes, Terence Tumenta, Carmen Black, and Joao P. De Aquino: “What Would Equitable Harm Reduction Look Like?”
The financial generosity of the pharmaceutical industry to provide funding for medical education tempts a compromise of professional standards and ethics.
In April 2002, many pharmaceutical companies adopted PhRMA code, an attempt to self-regulate the pharmaceutical industry's marketing to physicians and other health care professionals.
AMA Code opinions about collaborative care, health inequity, financial barriers to health care access, and physician responsibilities for safe patient discharge from health care facilities can apply to MLPs.
AMA J Ethics. 2024; 26(8):E622-625. doi:
10.1001/amajethics.2024.622.